title: Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin.
abstract: This study assessed hemostatic effects of an HMC-CoA reductase inhibitor, atorvastatin, on different parameters in 32 hypercholesterolemic patients of both sexes. In the patients and in 25 control subjects, plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor (PAI-1), D-dimer, prothrombin fragment 1 + 2 (F1 + 2), total cholesterol, triglycerides and fibrinogen had been measured. All these parameters were evaluated in patients after 6 and 12 months of treatment with atorvastatin at a dosage of 20 mg/day. This treatment significantly lowered the total cholesterol level in all patients. Moreover, after 6 months of atorvastatin treatment, PAI-1 and F1 + 2, which were both increased at baseline, were significantly reduced. This reduction continued after 12 months. The present results show that a reduction of hemostatic abnormalities, which exist in hypercholesterolemia, may be another important effect of the atorvastatin therapy.
authors: Department of Internal Medicine, University of Messina, Messina, Italy. Aldo.Trifiletti@unime.it
authors: A
authors: A
authors: Trifiletti
authors: A
authors: A
authors: Lasco
authors: R
authors: R
authors: Scamardi
authors: M A
authors: MA
authors: Pizzoleo
authors: A
authors: A
authors: Gaudio
authors: R
authors: R
authors: La Rocca
authors: E
authors: E
authors: Morini
authors: N
authors: N
authors: Frisina
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011516:Prothrombin; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000924:Anticholesteremic Agents; D015415:Biomarkers; D006538:Heptanoic Acids; D008055:Lipids; D010446:Peptide Fragments; D017395:Plasminogen Activator Inhibitor 1; D011758:Pyrroles; C045879:prothrombin fragment 1.2; D011516:Prothrombin; D002784:Cholesterol; D000069059:Atorvastatin